A number of research firms have changed their ratings and price targets for Cara Therapeutics (NASDAQ: CARA): 8/13/2015 – Cara Therapeutics was upgraded by analysts at Zacks from a “sell” rating to a “buy” rating. They now have a $25.00 price target on the stock. According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. […]
